Regeneron to present Phase 3 C-POST update for Libtayo in high-risk CSCC at ESMO 2026
Regeneron will present a Phase 3 C-POST overall survival update for adjuvant Libtayo in high-risk cutaneous squamous cell carcinoma (CSCC) at the ESMO 2026 congress in Madrid on Oct. 25. The company also plans to present data on Factor XI antibodies and a Phase 2 neoadjuvant Libtayo analysis.